Drug Profile


Alternative Names: ARRY-334543; ARRY-543; ASLAN-001; QBT01; SPS4370; Varlitinib tosylate

Latest Information Update: 18 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; ASLAN Pharmaceuticals
  • Class Antineoplastics; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; ERBB 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Biliary cancer; Cholangiocarcinoma; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Biliary cancer
  • Phase II Breast cancer; Cholangiocarcinoma; Gastric cancer
  • Phase I Solid tumours

Most Recent Events

  • 01 Aug 2017 Aslan Pharmaceuticals plans a phase II trial for Biliary cancer (Combination therapy, Metastatic disease, Late-stage disease) (NCT03231176)
  • 02 Jun 2017 Efficacy, adverse events and pharmacodynamics data from a phase Ib trial in Solid tumours presented at the (53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 28 Apr 2017 Aslan Pharmaceuticals plans a phase II/III trial for Gastric cancer (First-line therapy, Combination therapy, Metastatic disease, Late-stage disease) (NCT03130790)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top